This inventor holds 3 USPTO granted patents. Top assignee: Schering Aktiengesellschaft. Active years: 2005-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005-2008
Title: Arndt J G Schottelius: Pioneer in Inflammation Inhibitor Innovations
Introduction: Arndt J G Schottelius is a notable inventor based in Berlin, Germany, recognized for his significant contributions to the field of medicinal chemistry. With a total of three patents to his name, Schottelius has focused on advancing research related to inflammation inhibitors, showcasing the potential of quinoline and isoquinoline derivatives in therapeutic applications.
Latest Patents: Schottelius's latest inventions revolve around quinoline and isoquinoline derivatives, including a process for their production and their use as inflammation inhibitors. The patents detail the general formula of these compounds and emphasize their importance in combating inflammation-related conditions, highlighting his innovative approach to drug development.
Career Highlights: Throughout his career, Arndt J G Schottelius has been associated with Schering Aktiengesellschaft, a leading pharmaceutical company. His work there has played a pivotal role in developing new therapeutics aimed at treating complex health issues. His three patents reflect his commitment to enhancing healthcare through scientific innovation.
Collaborations: Schottelius has collaborated with esteemed colleagues such as Stefan Jaroch and Manfred Lehmann. These collaborations have likely enriched his research and contributed to the advancement of their collective knowledge in medicinal chemistry and drug development.
Conclusion: Arndt J G Schottelius stands out as an influential figure in the realm of medical inventions, particularly within the niche of inflammation inhibitors. His innovative patents on quinoline and isoquinoline derivatives demonstrate his dedication to improving healthcare outcomes and underline the significance of collaboration in the scientific community. As his work continues to evolve, Schottelius’s contributions will undoubtedly leave a lasting impact on the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile